www.covid-19vaccinetracker.org Open in urlscan Pro
54.194.170.100  Public Scan

Form analysis
0 forms found in the DOM

Text Content

DNA-Based
RNA-Based
Live attenuated
Inactivated Virus
Protein subunit
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Overview
HOW TO READ THE SYRINGE Graphic
Timeline
HOW Vaccines work
Stages of Development
Early Manufacturing
A Race ARound the World
list of vaccines by Category

Inactivated Virus
Live attenuated
Protein subunit
DNA-Based
RNA-Based
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Vaccines in use


Data sourced from FasterCures, a center of the Milken Institute.

Interactive visualization by FirstPerson, a design & storytelling company.


Covid-19 Vaccine Tracker
Rapidly evolving, check back often.

Last updated:
August 18, 2022 10:40 AM
PST
276
vaccines are in development.
109
are now in clinical testing.
24
are in use.
See which vaccines are in use—and the newest updates.

The race to develop, approve, and manufacture COVID-19 vaccines is fluid—and
urgent.

Scroll
Leading Vaccines
Phase

BioNTech/Pfizer
Approved
Moderna
Authorized
Oxford/AstraZeneca

Authorized
Janssen Pharma

Authorized
Sinovac/Instituto Butantan
Phase III
Wuhan Inst./Sinopharm
Phase III
Beijing Inst./Sinopharm

Phase III
Gamaleya Research Inst.

Phase III
CanSino Biologics

Phase III
Novavax
Phase III
vaccines in use

Key
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Vaccine Categories









Phases
I
Phase One
II
Phase Two
III
Phase Three
RR
Regulatory Review
AU
Authorized

View on desktop for the full experience.
View data for vaccines and treatments.

HOW TO READ THE
SYRINGE Graphic

There are currently

These fall into

At this time,
But not all vaccines are created equal.

276
vaccines in development for COVID-19.
This syringe represents vaccines currently in development. Each row is an
individual vaccine.
How many are out of the pre-clinical phase?

9
different product categories/platforms.
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Vaccine Categories










More about the timeline, phases, manufacturing, and approaches to develop a
COVID-19 vaccine.


Clinical trial phases read in columns from left to right on the syringe.
109
vaccines are in clinical testing.

I
II
III
RR
AU


Timeline

The vaccine development process typically takes a decade, but COVID-19 timelines
are being compressed due to the global urgency of the pandemic.
Typical Vaccine Development


Possible COVID-19 vaccine development
12-18 MOnths

~10 Years
Many suggested a timeline from start of development to public use would be 12
-18 months from January 2020, when the genetic sequence of the virus that causes
COVID-19 was published.

After completing large-scale clinical trials, the BioNTech/Pfizer vaccine was
the first to be authorized for emergency use after 11 months.

How Vaccines Work


Weak Germs Injected
Vaccines contain the same germs that cause the disease, either killed or
weakened, or they contain genetic instructions that code for the disease.

Antibodies Created
They stimulate your immune system to produce antibodies, as if you were exposed
to the germ.

Immunity Developed
After getting vaccinated, one develops immunity to that disease without having
to get it first.
Vaccines don’t cure diseases.

They prevent them.

stages of development
After pre-clinical studies are completed, the multiple phases of the clinical
trial process test whether new vaccines are safe and effective before going
public—culminating in a regulatory review. Phase IV is post-approval and
monitors real-world effectiveness.
This process usually takes approximately 10 years, but governments and industry
are fast-tracking these vaccines while maintaining safety and efficacy
standards.
PRE

Pre-Clinical Phase
 * Collects data to support feasibility and safety
   
 * Involves iterative non-human testing
 * Evaluates toxic and pharmacological effects
 * Normally occurs before human testing can begin


I

Clinical phase
 * Small study of healthy people
   
 * Evaluates safety and immune response at different doses
 * Typically takes 1-2 years, but for COVID-19 trials, expected to take 3 months


II

Clinical phase
 * Studies 100s of people
   
 * Further evaluates safety, assesses efficacy, and informs optimal dose and
   vaccine schedule
 * Typically takes 2-3 years, but for COVID-19 trials, expected to take 8 months


III

Clinical phase
 * Studies 1000s of people
   
 * Further evaluates safety and efficacy
 * Typically takes 2-4 years, but for COVID-19 trials, may be combined with
   Phase II


RR

Regulatory Review
 * Government agency reviews trial data and licensing application information
   before authorization
   
 * Can happen while manufacturing has started
 * Typically takes 1-2 years, but for COVID-19, expedited to take a few months


IV

Clinical Phase
 * Post-approval studies that monitor effectiveness in real-world conditions
   
 * Testing begins after vaccine has been released to public


Once a vaccine is approved, do we get it right away?

Early Manufacturing
Oftentimes developers will try to ensure that enough of a vaccine is ready to
ship the moment approval comes in by beginning the manufacturing process during
clinical trials.
But a manufacturer loses significant resources if approval doesn’t come or a
vaccine is no longer needed in the marketplace. The more vaccines produced, the
more risk incurred. To mitigate risk and encourage manufacturing, governments,
industry and international organizations are working together.
Pre
I
II
III
RR
IV

NON-IDEAL CASE
Developer manufactures mass quantities of a vaccine, but does not get approval,
leaving the public without a vaccine and resources put into manufacturing lost.
For COVID-19 vaccine development, private philanthropy has pledged to pay the
lost costs for this scenario.
Pre
I
II
III
RR
IV

GOOD CASE
Developer gets fast approval, but has not manufactured enough of a vaccine to
distribute in mass quantities. The public must wait longer for more vaccines to
become available.
Pre
I
II
III
RR
IV

BEST CASE
Developer gets fast approval and has been concurrently manufacturing the vaccine
during clinical trials.
The vaccine is now ready to distribute in mass quantities.
A race ARound the world
To expedite development and distribution of a vaccine, unprecedented
international alliances have been formed and billions have been allocated. But
simultaneous initial development will eventually give way, and only a select few
of the most promising candidates will receive funding towards eventual licensing
and distribution.

That is why many different types of vaccines are being researched and
tested—some traditional, others experimental. Each product category has its own
advantages and disadvantages, and we will likely need more than one vaccine to
protect all people around the globe.


Meet the candidates.

DNA-Based
RNA-Based
Live attenuated
Inactivated Virus
Protein subunit
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Inactivated Virus
Live attenuated
Protein subunit
DNA-Based
RNA-Based
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Inactivated virus
These consist of viruses grown in culture and then killed as a means to reduce
virulence (ability to infect and cause harm) and thus prevent infection from the
vaccine. One benefit is they can be given to people with weakened immune
systems. Examples include polio and influenza vaccines.
Bharat Biotech/ Indian Council of Medical Research/ National Institute of
Virology/ Ocugen/ Precisa Medicamentos
Inactivated; whole-virion (COVAXIN) (BBV152)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
World Health Organization (WHO) granted Emergency Use Listing (EUL) on
11/3/2021; Phase III efficacy analysis results announced on 7/2/2021; Phase III
second interim analysis results announced on 4/21/2021; Authorized for
"emergency use" in Nepal and Zimbabwe as of March 2021; Phase II interim
analysis and Phase I follow-up results published 3/8/2021; Phase III interim
analysis results announced 3/3/2021; Neutralization of UK-variant with
vaccine-elicited sera announced January 2021; India granted "permission for
emergency use" on 01/03/2021; Phase I and II safety and immunogenicity data
released December 2020 and published January 2021; Phase III began November
2020; Phase I/II study: Phase I began July 2020 and Phase II began September
2020, initial results expected September 2020; Animal study results released
September 2020, Approved for intranasal booster dose trials February 2022
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976,
NCT04641481
Valneva/ Dynavax/ National Institute for Health Research, United Kingdom
Inactivated (Inactivated + CpG 1018), VLA2001
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Japanese Encephalitis
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III positive topline results announced 10/18/2021; Commenced recruitment
of adolescents (12-17 years) into Phase III trial “Cov-Compare” and enrolled
participants in the Phase I/II booster trial in September 2021; Initiated a
further Phase III trial with participants aged 56 years and older in August
2021; Phase III began April 2021; Phase I/II data announced April 2021; Phase
I/II began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04671017, NCT04864561
Sinovac/ Instituto Butantan/ Bio Farma
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc); VACSERA in
Egypt
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
The Egyptian Drug Authority (EDA) granted the Sinovac/VACSERA vaccine an
emergency use license on 8/23/2021; Phase I/II clinical trials results in
healthy children and adolescents aged 3-17 in China published 6/28/2021; World
Health Organization (WHO) granted Emergency Use Listing (EUL) on 6/1/2021;
Summary of clinical trial data released on 4/3/2021; Emergency use approval, or
conditional marketing authorization, has been granted by over 30 countries as of
4/1/2021; Malaysia granted "conditional approval" on 3/2/2021; China's NMPA
granted "conditional marketing authorization" on 2/8/2021; Phase III results
(Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety,
tolerability, and immunogenicity data in adults aged 60 years and older
published on 2/3/2021; Sinovac filed for "conditional market authorization" with
China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile
granted "emergency use" approval on 1/20/2021; Brazil granted "temporary
authorization for emergency use" on 1/17/2021; Turkey granted "emergency use
authorization" on 1/31/2021; Indonesia granted "emergency use approval" on
01/11/2021; Phase III efficacy results (Brazil) released early January 2021;
Phase I/II complete analysis results published 11/17/2020; Phase III trial
resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on
11/09/2020; Received approval for Phase I/II trial in adolescents and children
in September 2020; Phase III trial began end of July 2020; Phase II began June
2020, mid-phase II results released August 2020; Preliminary results from Phase
I/II trials released June and September 2020 (aged 60+) 2020; Received early
approval for "emergency use" in China (Aug 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04383574, NCT04352608, NCT04456595, NCT04551547, NCT04508075, NCT04582344,
NCT04617483, NCT04651790, 669/UN6.KEP/EC/2020
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Inactivated, (QazCovid-in®)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Kazakhstan lauched nationwide vaccine roll out as of 4/27/2021; Kazakhstan
granted "temporary registration for nine months" as of 1/13/2021; Phase III
began December 2020; Phase I/II began September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04530357, NCT04691908
Beijing Institute of Biological Products/ Sinopharm
Inactivated, (BBIBP-CorV)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Vietnam granted approval on 6/4/2021; World Health Organization (WHO) granted
Emergency Use Listing (EUL) on 5/7/2021; Indonesia granted "emergency use"
approval on 4/30/2021; Hungary granted "emergency use" approval on 1/29/2021;
Pakistan granted "emergency use authorization" on 1/18/2021; China "granted
conditional market approval" on 12/31/2020; Midterm clinical results released on
12/30/2020; Bahrain National Health Regulatory Authority (NHRA) "approved" on
12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced "official
registration" on 12/9/2020, following review of Phase III interim analysis;
Phase I/II results published October 2020; Phase III trial began July 2020;
Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep
2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459, ChiCTR2000034780, NCT04510207, NCT04560881
Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co.,
Ltd.
Inactivated SARS-CoV-2 vaccine, Vero cell, (KCONVAC)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Indonesia granted "emergency use authorization" in November 2021; Phase III
began June 2021; Received early approval for "emergency use" in China in May
2021; Phase I/II results announced April 2021; Phase I/II study began October
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000038804, ChiCTR2000039462, NCT04758273, NCT04756323, NCT04852705
Erciyes University
Inactivated; (ERUCOV-VAC), (TURKOVAC)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase II dosed February 2021; Phase I began November
2020, completed on December 14, 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04691947, NCT04824391, NCT04942405
Wuhan Institute of Biological Products/ Sinopharm
Inactivated
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
China granted "conditional approval" on 2/25/2021; Applied for regulatory
approval in China as of February 2021; Phase III trial began July 2020; Phase
I/II early trial results released June 2020, Phase I/II interim analysis
published August 2020; Received early approval for "emergency use" in China (Aug
2020) and the UAE (Sep 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000, NCT04510207, NCT04612972
Kocak Farma Ilac ve Kimya San. A.S.
Inactivated
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04838080, NCT04942405, NCT05035238
Chumakov Federal Scientific Center for Research and Development of Immune and
Biological Products of the Russian Academy of Sciences
Whole virion inactivated vaccine, CoviVac
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began March 2021; Russia "registered" the vaccine in February 2021;
Clinical trials began Ocotober 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Institute of Medical Biology, Chinese Academy of Medical Sciences
Inactivated
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I
began May 2020, results released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412538, NCT04470609, NCT04659239
Shifa Pharmed Industrial Co
COVID-19 inactivated vaccine (COVIran Barekat)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study in children ages 12-18 began November 2021; Iran granted emergency
use authorization on 6/14/2021; Phase II/III trial in adults 18-75 years of age
began March 2021; Phase I trial in adults 51-75 years of age began March 2021;
Phase I trial in adults 18-50 years of age began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IRCT20201202049567N1, IRCT20201202049567N2, IRCT20201202049567N3
Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH
Inactivated, Newcastle Disease Virus (NDV) based chimeric vaccine with or
without the adjuvant CpG 1018; (NDV-HXP-S)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04764422
KM Biologics
Inactivated (inactivated + alum); (KD-414)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for JE, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II study began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2071200106
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing
membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro)
+ CpG 1018, (COVIVAC)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, Phase I is expected to be completed by end of May
2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04830800
Laboratorio Avi-Mex/ National Council of Science and Technology, Mexico/ Agencia
Mexicana de Cooperación Internacional para el Desarrollo (AMEXID)
Recombinant Newcastle disease virus (rNDV), ("Patria")
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04871737, NCT05205746
Scientific and Technological Research Council of Turkey (TUBITAK)
Adjuvanted inactivated vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began end of April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04866069
National Research Centre, Egypt
Inactivated; whole virus; (NRC-VACC-01)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study results published March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Institute Butantan (Brazil) / Dynavax / PATH
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing
membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro)
+ CpG 1018
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Sinovac/ Dynavax
Inactivated + adjuvant (CpG 1018)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Selcuk University
Inactivated
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Osaka University / BIKEN / NIBIOHN
Inactivated
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher


Product Description
PRE
I
II
III
RR
AU
Live attenuated virus
In contrast to inactivated virus vaccines, these vaccines, also whole viruses,
are live to elicit a stronger immune response but weakened to reduce virulence.
Examples include those for measles, mumps, and tuberculosis.
Codagenix / Serum Institute of India
Single-dose, intranasal, live attenuated vaccine, (COVI-VAC)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I topline safety and immunogenicity data and ongoing acceleration into
Phase II/III trials announced September 2021; Pre-clinical research published
June 2021; Phase I trial dosed January 2021, initial data expected by mid-2021;
Phase I recruitment began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04619628, NCT05233826
Meissa Vaccines 
Intranasal live-attenuated chimeric vaccine candidate, (MV-014-212)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Preliminary clinical data on safety and immunogenicity released October 2021;
Pre-clinical data released August 2021; Phase I enrollment began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04798001
Indian Immunologicals Ltd/ Griffith University
Codon deoptimized live attenuated virus
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.
Codon deoptimized live attenuated vaccines
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU
Protein subunit
Rather than introducing whole viruses to an immune system, a fragment of the
virus is used to trigger an immune response and stimulate immunity. Examples
include the subunit vaccines against Hepatitis B and shingles.
Sanofi Pasteur/ GSK
Protein subunit; S protein, baculovirus production; (Vidprevtyn)
Product Description

Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of
Health and Human Services (HHS)/ US Department of Defense (DoD)
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved
vaccine)
Anticipated Next Steps
Anticipated Next Steps
n/a
EMA began rolling review on 7/20/2021; Phase III began end of May 2021; Phase II
interim results released May 2021; Phase II with refined antigen formulation
began February 2021; Phase I/II interim safety and immunogenicity results
released January 2021; Phase IIb expected to begin February 2021; Phase I/II
interim results announced December 2020; Phase I/II began September 2020;
Selected for US Operation Warp Speed in April 2020 and awarded funding in July
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04537208, NCT04762680, PACTR202011523101903
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth
Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda
Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo
Protein subunit; Full length recombinant SARs COV-2 glycoprotein nanoparticle
vaccine adjuvanted with Matrix M; (NVX-CoV2373) (SARS-CoV-2 rS)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates
Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Indonesia and the Philippines granted emergency use authorization (EUA) as of
November 2021; Announced rolling regulatory submission to the U.K. Medicines and
Healthcare products Regulatory Agency (MHRA) for authorization on 10/27/2021;
Phase III (U.K. trial) final analysis results published 6/30/2021; Phase III
efficacy data released 6/14/2021; Updated PREVENT-19 trial protocol released on
5/10/2021; Announced preclinical data from NanoFlu/NVX-CoV2373 combination
vaccine study on 5/10/2021; Initiated a pediatric expansion (12-17 years of age)
of its Phase III clinical trial on 5/3/2021; Announced participation in Phase II
clinical trial called "Comparing COVID-19 Vaccine Schedule Combinations – Stage
2" (Com-COV2) on 4/14/2021; Announced the initiation of crossover arms in two
ongoing clinical trials on 4/5/2021; Phase III (UK) and Phase IIb ( South
Africa) final efficacy results released 3/11/2021; Phase I/II trial dosed in
Japan on 2/26/2021; Phase III trial (PREVENT-19) completed enrollment in the US
and Mexico on 2/22/2021; Announced the start of the rolling review process with
several regulatory agencies worldwide on 2/4/2021, including the European
Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines
and Healthcare products Regulatory Agency (MHRA), and Health Canada; Phase III
(UK) and Phase IIb ( South Africa) interim results released 1/28/2021; Phase III
trial (PREVENT-19) initiated in the US and Mexico in December 2020, trial
protocol released on website; FDA granted Fast Track Designation on 11/9/2020;
Phase III dosed in the UK in October 2020, trial protocol released on website,
interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020;
Selected for US Operation Warp Speed July 2020; Phase I/II began end of May
2020, interim data expected to be released on 10/30/2020; Animal study &
preliminary Phase I results released Aug 2020, Phase I results published Sept
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-004123-16, NCT04368988, NCT04533399, NCT04583995, NCT04611802
Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese
Academy of Sciences
Adjuvanted recombinant protein (RBD-Dimer); ( ZF2001)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
China and Uzbekistan granted "emergency use" approval in March 2021; Phase III
began December 2020; Phase I and II safety and immunogenicity data released
December 2020; Phase II began July 2020; Received approval to launch clinical
trials in China in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445194, NCT04466085, NCT04550351, NCT04646590
Center for Genetic Engineering and Biotechnology (CIGB), Havana
CIGB-66 (RBD + aluminum hydroxide)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III
began March 2021; Phase II began February 2021, Phase I (ABDALA) trial began
December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RPCEC00000346
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax
MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Announced (10/26/2021) as one of two candidate vaccines to be included in the
Solidarity Trial Vaccines with WHO and the Ministries of Health of Colombia,
Mali, and the Philippines; Phase III began October 2021; Taiwan began vaccine
rollout during the week of 8/23/2021; Phase III expected to complete the
recruitment (1,000 participants) by Q3 2021; Taiwan granted EUA approval on
7/19/2021, clinical trials are ongoing; Phase II interim analysis results
released 6/10/21; Phase II study in elderly adults (65 years and older) began
May 2021; Booster trial with third dose began May 2021; Phase II second dose
vaccination completed on 4/28/2021; Phase I interim analysis results announced
4/7/2021; Phase II dosed January 2021; Phase I dosed in early October 2020;
Received conditional approval for clinical testing on Aug 31 and was given full
approval on Sept 30; Pre-clinical data released August 2020 and published
November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04487210, NCT04695652, NCT04822025, NCT04951388
Razi Vaccine and Serum Research Institute
SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Iran issued an emergency use license in November 2021; Phase III began September
2021; Phase II began April 2021; Phase I began February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IRCT20201214049709N1, IRCT20201214049709N2, IRCT20201214049709N3
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford
Expression Technologies
Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19),
(SpikoGen)
Product Description

Funder
Funder
n/a
Innovate UK/ Australian Government
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Iran issued an emergency use permit in October 2021; Phase III trial dosed
August 2021; Phase II trial dosed June 2021; Phase II and III trials will be
initiated in Iran in the coming weeks as of May 2021; Phase I trial dosed July
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04453852, NCT04944368, NCT05005559, IRCT20150303021315N23,
IRCT20150303021315N24
Biological E Ltd/ Dynavax/ Baylor College of Medicine
Protein subunit; (BECOV2)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began September 2021; Phase III clinical trial received approval to
start by CDSCO in April 2021; CEPI partnership announced December 2020; Phase
I/II began November 2020, interim data expected Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/11/029032, CTRI/2021/08/036074
Instituto Finlay de Vacunas
rRBD produced in CHO-cell chemically conjugate to tetanus toxoid; (FINLAY-FR-2)
(SOBERANA 02); PastuCovac in Iran
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Cuba granted "emergency approval" on 8/20/2021; Iran began producing the vaccine
(as PastuCovac) in August 2021; Phase III efficacy data announced 7/8/2021;
Phase III preliminary data announced on 6/19/2021; Phase I/II pediatric study
(ages 3-18 years) began June 2021; Cuba began rolling out the vaccine in a mass
campaign in May 2021; Phase III began March 2021; Phase II began December 2020;
Phase I began October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IFV/COR/06 (RPCEC00000340), IFV/COR/08 (RPCEC00000347), IFV/COR/09
(RPCEC00000354)
Nanogen Pharmaceutical Biotechnology
Recombinant SARS-CoV-2 spike protein, aluminum adjuvanted, (Nanocovax)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase II began February 2021; Phase I began December
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04683484, NCT04922788
Federal Budgetary Research Institution (FBRI) State Research Center of Virology
and Biotechnology "VECTOR"
Peptide vaccine, EpiVacCorona
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II interim results published March 2021; Phase III trial began November
2020; "Registered" for use in Russia in October 2020; Phase I/II trial began end
of July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04527575, NCT04780035
Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan
Recombinant protein vaccine S-268019, baculovirus expression
Product Description

Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III began October 2021; New Phase I/II clinical trial began in Japan at
the end of July 2021, using a new formulation with a modified adjuvant to
achieve a higher neutralizing antibody titer; Phase I/II clinical trial began
December 2020. Results of 1/2 trial released December 2021. Top line results for
Phase 2/3 additional dose released March 2022.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2051200092
Clover Biopharmaceuticals Inc./ Dynavax
Protein subunit, native like trimeric subunit spike protein; (SCB-2019)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, RSV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III (SPECTRA) trial succesfully met primary and secondary efficacy
endpoints as of September 2021; Phase II/III (SPECTRA) trial with Dynavax
adjuvant dosed March 2021, fully enrolled as of July 2021; Clover and GSK
discontinued their partnership as of February 2021; Phase I safety and
immunogenicity data released December 2020 and published January 2021; Phase
II/III trial with Dynavax adjuvant expected to begin during first half of 2021;
Phase II/III trial with GSK adjuvant is not expected to move forward;
Pre-clinical results released September 2020; CEPI partnership expanded in July
and November 2020, Phase I trial began June 2020, preliminary results expected
in the near future
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405908, NCT04672395
Instituto Finlay de Vacunas
RBD + adjuvant booster dose that contains spike-protein fragments, (SOBERANA
PLUS)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Cuba granted emergency use authorization for use in convalescent individuals (19
years of age and older) on 9/23/2021; Phase I/II study in convalescent pediatric
individuals (2-18 years of age) began September 2021; Phase II study in
convalescent individuals began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IFV/COR/11 (RPCEC00000366), IFV/COR/15 (RPCEC00000391)
Vaxxinity, Inc. (formerly COVAXX and United Neuroscience)/ University of
Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia
S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP); UB-612
Product Description

Funder
Funder
n/a
Ministry of Health and Welfare in Taiwan
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study extended with one booster dose in July 2021; Phase II/III trials
expected to begin in Brazil, India, and other countries in Q2 2021; Phase I
interim data announced 2/8/2021; Phase II began (Taiwan) February 2021; Phase II
clinical trials granted conditional approval by Taiwan's Ministry of Health and
Welfare on 1/29/2021; Phase I began (Taiwan) September 2020; Large scale human
efficacy clinical trials expected to be conducted in Brazil and the US
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04545749, NCT04683224, NCT04773067, NCT04967742
AdaptVac (PREVENT-nCoV consortium)
Protein subunit, capsid-like particle (CLP); (ABNCoV2)
Product Description

Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II (COUGH-1) study began March 2021, initial results expected to be
released in July 2021; Pre-clinical data published January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

West China Hospital, Sichuan University
RBD (baculovirus production expressed in Sf9 cells)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began November 2020; Phase I began end of August 2020; Animal study
data published July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000037518, ChiCTR2000039994, NCT04530656, NCT04640402, NCT04718467
Laboratorios Hipra, S.A.
Recombinant Protein RBD
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05007509
SK bioscience/ GSK/ Institute for Protein Design (IPD) at the University of
Washington (UW)
SARS-CoV-2 recombinant protein nanoparticle vaccine, (GBP510)
Product Description

Funder
Funder
n/a
Gates Foundation/ Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II final data announced November 2021; Phase I/II interim data announced
August 2021; Phase III IND submitted to the Korean Ministry of Food and Drug
Safety in June 2021; Phase I/II began February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04742738, NCT04750343
University Medical Center Groningen/ Akston Biosciences Corporation/ LakePharma
SARS-CoV-2-RBD-Fc fusion protein; (AKS-452)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II dosed April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04681092
VIDO-InterVac, University of Saskatchewan
Protein subunit, adjuvanted microsphere peptide, (COVAC-1 & COVAC-2)
Product Description

Funder
Funder
n/a
The Government of Saskatchewan and the Canadian Federal Government
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II dosed February 2021; Animal testing results expected in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04702178
Kentucky BioProcessing (British American Tobacco)
RBD-based, (KBP-COVID-19)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began recruiting December 2020, results expected mid-2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04473690
National Vaccine and Serum Institute, China
Recombinant SARS-CoV-2 Vaccine (CHO Cell)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began recruiting April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04869592
Instituto Finlay de Vacunas
RBD + Adjuvant (FINLAY-FR-1) (SOBERANA 01)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I preliminary report released March 2021; Phase I/II began August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IFV/COR/04 (RPCEC00000332), IFV/COR/05 (RPCEC00000338)
Center for Genetic Engineering and Biotechnology (CIGB), Havana
CIGB-669 (RBD-AgnHB)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I of Phase I/II (MAMBISA) trial began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RPCEC00000345
University Hospital Tuebingen
SARS-CoV-2 HLA-DR peptides, (CoVAC-1)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04546841
OSE Immunotherapeutics/ Cenexi
T cell-based vaccine platform (CoVepiT)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
First positive results announced 11/30/21; Phase I began May 2021; Pre-clinical
results released in August 2020. Positive results released December 2021.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04885361
Baiya Phytopharm/ Chula Vaccine Research Center
Plant-based subunit (RBD-Fc + Adjuvant)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began September 2021; Animal trial results announced September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04953078
Emergex Vaccines Holdings/ Center for Primary Care and Public Health (Unisante)/
University of Lausanne, Switzerland/ University of Lausanne Hospitals
T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19, (naNO-COVID)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I (Stage II of a 2-part adaptive trial) began recruiting in December 2021
and is expected to be dosed in January 2022
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05113862
HK inno.N Corporation (formerly CJ HealthCare)
SARS-CoV-2 Vaccine, (IN-B009)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began September 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05113849
Yisheng Biopharma
PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I clinical trial registered August 2021; Pre-clinical data published March
2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12621001009808
Adimmune Corporation
Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II dose finding study has received approval to begin in Indonesia as of
September 2021; Phase I began end of August 2020; Phase II expected to begin
November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04522089
Shanghai Zerun Biotechnology Co., Ltd/ Walvax Biotechnology Co., Ltd
Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell); (202-CoV )
Product Description

Funder
Funder
n/a
Coalition for Epidemic Prepardeness (CEPI)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began July 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04982068
Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and
Development Command
Protein subunit; S protein (SpFN)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began recruiting April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04784767
Guangdong Provincial Center for Disease Control and Prevention/ Gaozhou Center
for Disease Control and Prevention
Recombinant SARS-Cov-2 coronavirus fusion protein vaccine, (V-01)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2100045108, ChiCTR2100045107
University of Queensland/CSL/Seqirus
Protein subunit; molecular clamp stabilized Spike protein with MF59 adjuvant
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal
Government (Australia)/Paul Ramsay Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial began July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12620000674932p, ISRCTN51232965, NCT04495933
PT Bio Farma
SARS-CoV-2 Protein Subunit Recombinant Vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II expected to begin November 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05067894
Sinocelltech Ltd.
Bivalent Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Variants,
(SCTV01C)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II/III, multicenter, randomized, double-blinded trials (designed to
evaluate the safety, tolerability, immunogenicity, and protective efficacy of
SCTV01C in healthy population aged ≥18 years previously vaccinated with
inactivated, adenovirus vectored, or mRNA COVID-19 vaccine) expected to begin
late October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05043311, NCT05043285
Clover Biopharmaceuticals AUS Pty Ltd
Adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant)
subunit vaccine; (SCB-2020S)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin August 2021; Pre-clinical data announced May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04950751
VaxForm
CoV2-OGEN1, protein-based vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04893512
PDS Biotechnology
PDS-0203; Versamune T-cell activating technology
Product Description

Funder
Funder
n/a
The Ministry of Science, Technology and Innovation of Brazil (MCTI)
Related use
Related use
n/a
Same platform as vaccines against cancers, HBV, influenza, and tuberculosis
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II is expected to to begin by Q2/3 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Intravacc/Epivax
Outer Membrane Vesicle (OMV)-subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data announced April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton
Killam Health Center, Nova Scotia Health Authority, Canadian Immunization
Research Network, University of Laval, Global Urgent and Advanced Research and
Development in Canada
Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in
LNP
Product Description

Funder
Funder
n/a
National Research Council of Canada Industrial Research Assistance Program (NRC
IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation
Manufacturing Canada (NGen)
Related use
Related use
n/a
Same platform as vaccine candidates for cancer and infectious diseases,
including malaria and anthrax
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II expected to begin by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Flow Pharma
Protein subunit, peptide
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza,
HPV therapeutic vaccine, Breast Cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study results published May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Generex / EpiVax
Protein subunit; Ii-Key peptide
Product Description

Funder
Funder
n/a
Beijing Youfeng Biological Technology, Ltd (Youfeng-BI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, SARS-CoV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Vaxil Bio
Protein subunit; peptide
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Vaxil has put its COVID-19 vaccine work on temporary hold as of May 31, 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Bogazici University
Peptide + novel adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Clinical trials expected to begin summer 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

LakePharma, Inc.
Protein subunit, nanoparticle vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano
Heredia (UPCH)
RBD protein (baculovirus production) + FAR-Squalene adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

MOGAM Institute for Biomedical Research, GC Pharma
Protein subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Axon Neuroscience SE
Peptides derived from Spike protein; (ACvac1)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Vabiotech
Protein subunit, recombinant S protein in IC-BEVS
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Neo7Logix
Peptides
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Ohio State University/ Kazakh National Agrarian University
RBD protein delivered in mannose-conjugated chitosan nanoparticle
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Tampere University
Recombinant S protein produced in BEVS
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for
Especially Dangerous Infections
Recombinant spike protein with Essai O/W 1849101 adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Kazakh National Agrarian University
Recombinant spike protein with Essai O/W 1849101 adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Max-Planck Institute of Colloids and Interfaces
Recombinant S protein
Product Description

Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

AnyGo Technology
Protein subunit, recombinant S1-Fc fusion protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Izmir Biomedicine and Genome Center
Recombinant S protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

iBio / CC-Pharming
Protein subunit; Subunit protein, plant produced
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

BiOMVis Srl/ University of Trento
OMV-based vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing
Protein subunit (gp-96 backbone)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal data released August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunit, recombinant protein, nanoparticles (based on S-protein and
other epitopes)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

ImmunoPrecise/ LiteVax BV
Spike-based (epitope screening)
Product Description

Funder
Funder
n/a
TRANSVAC2
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Lomonosov Moscow State University
Structurally modified spherical particles of the tobacco mosaic virus (TMV)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

National Research Centre, Egypt
Protein Subunit S, N, M & S1 protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

EpiVax / University of Georgia
Protein subunit; S protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Inf H7N9
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Research Institute for Biological Safety Problems, Rep of Kazakhstan
Protein subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Baylor College of Medicine
Protein subunit; S1 or RBD protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Alberta
Protein subunit; spike based
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Hepatitis C
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Soligenix/ University of Hawaii at Mānoa
CiVax™ COVID-19 vaccine candidate; spike protein + novel adjuvant
Product Description

Funder
Funder
n/a
Soligenix, Inc.
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical testing results released in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Intravacc/Epivax
Outer Membrane Vesicle (OMV)-peptide
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Neovii/Tel Aviv University
RBD-based
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of California, San Diego
Protein subunit; plant virus nanotechnology formulated as injectable and
microneedle patch
Product Description

Funder
Funder
n/a
National Science Foundation (Rapid Response Research [RAPID] grant)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan
Protein subunit, VLP-recombinant protein + adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

InnoMedica
Protein subunit, TaliCoVax19
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso,
Oyo State, Nigeria
Subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Pittsburgh
PittCoVacc, Protein subunit, microneedle arrays S1 subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

OncoGen
Protein subunit, synthetic long peptide vaccine candidate for S and M proteins
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Innovax / Xiamen University / GSK
Protein subunit; COVID-19 XWG-03 truncated Spike proteins
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Applied Biotechnology Institute, Inc.
Orally delivered, heat stable subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

MIGAL Galilee Research Institute
Protein subunit; oral E. coli-based protein expression system of S and N
proteins
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Virginia
S subunit intranasal liposomal formulation with GLA/3M052 adjs.
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of San Martin and CONICET, Argentina
Protein subunit
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Quadram Institute Biosciences
OMV-based vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Flu A, plaque
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

ExpreS2ion
Protein subunit, drosophila S2 insect cell expression system VLPs
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Federal Budgetary Research Institution (FBRI) State Research Center of Virology
and Biotechnology "VECTOR"
Subunit vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

UMN Pharma (Shionogi)
Protein subunit; recombinant protein vaccine, utilizing baculovirus expression
vector system technology
Product Description

Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

EpiVax
Protein subunit EPV-CoV-19
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Sorrento Therapeutics
Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human
IgG Fc (T-VIVA-19)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results released July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

AJ Vaccines
Protein subunit; S protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Mynvax
RBD-protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Verndari/ University of California, Davis
Spike protein; VaxiPatch microneedle array dermal patch
Product Description

Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA) Division of
Research, Innovation, and Ventures (DRIVe)
Related use
Related use
n/a
Same platform as vaccines against influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Preliminary pre-clinical results are expected in the second half of 2020, Phase
I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in
August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Chulalongkorn University/ GPO, Thailand
RBD protein fused with Fc of IgG + Adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU


DNA-Based
These next-gen vaccines work through introducing viral genetic material (DNA)
that cells use to make viral proteins that induce a range of immune response
types. They can potentially be developed more quickly and easily than other
vaccines, but no DNA vaccines have been approved for human use.
Zydus Cadila Healthcare Limited
DNA; (ZyCoV-D) plasmid vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
India granted "emergency use approval" for use in adults and children aged 12
years and above on 8/20/2021; Applied to the office of Drug Controller General
of India (DCGI) for EUA on 7/1/2021; Phase III data expected to be announced May
2021; Phase III dosed January 2021; Pre-clinical results released January 2021;
DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase
I began July 2020 and Phase II began August 2020, initial results expected
September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026352, CTRI/2021/01/030416
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm
BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National
University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec
DNA; (INO-4800) plasmid vaccine with electroporation
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of
Defense
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III segment of INNOVATE trial has received regulatory authorizations to
proceed in Brazil, Colombia, India, Mexico, Philippines, Thailand, and the U.S.
as of 11/09/21; Announced (10/26/2021) as one of two candidate vaccines to be
included in the Solidarity Trial Vaccines with WHO and the Ministries of Health
of Colombia, Mali, and the Philippines; Phase III efficacy trial receives
authorization to proceed from Brazil's ANVISA on 8/26/2021; Phase II preliminary
results released on 5/7/2021; ex-US Global Phase III trial planning announced
4/23/2021; Study results on the human immune responses against variants of
concern announced 4/15/2021; Phase I data published December 2020; Phase II
dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA
partial clinical hold for planned Phase II/III trial reported on 9/28/2020;
Phase I/IIa trial began July 2020; Animal study results released July 2020;
Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim
data of ongoing study released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000038152, ChiCTR2000040146, NCT04336410, NCT04447781, NCT04642638
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech
DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III trial began December 2020; Pre-clinical study results released
October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302)
2020, results expected during Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2051200085, jRCT2051200088, NCT04463472, NCT04527081, NCT04655625
Vaccibody AS
Second generation DNA plasmid vaccine, T-cell; VB10.2210 (C2)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05069623
Vaccibody AS
Second-generation DNA plasmid vaccine, RBD; VB10.2129 (C1)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05069623
Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced
Institute of Science and Technology (KAIST), Pohang University of Science and
Technology (POSTECH)/ Binex/ PT Kalbe Pharma
DNA; (formerly GX-19) (GX-19N)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III study expected to begin in Indonesia as of July 2021; Phase IIa
began February 2021; Updated development plan to GX-19N formula and will
reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study
began end of June 2020; Animal study results announced August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445389, NCT04715997
GeneOne Life Science
DNA; (GLS-5310)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIa expected to be dosed July 2021; Phase I/IIa began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04673149
Entos Pharmaceuticals/ Cytiva
DNA; (Covigenix)
Product Description

Funder
Funder
n/a
Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/
Institute for Ageing (IA)/ National Research Council of Canada Industrial
Research Assistance Program (NRC IRAP)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04591184
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech
DNA (COVID-eVax)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, announced the authorization of the clinical trial
by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results
released in May and July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-003734-20, NCT04788459
Scancell/ University of Nottingham/ Nottingham Trent University
DNA; plasmid vaccine RBD&N
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I COVIDITY clinical trial dosed October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05047445
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of
Western Australia/ Telethon Kids Institute/ PharmaJet
DNA; (COVIGEN) needle-free delivery
Product Description

Funder
Funder
n/a
Australian Government Medical Research Future Fund (MRFF)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed end of June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04742842
Symvivo
DNA; bacTRL-Spike
Product Description

Funder
Funder
n/a
National Research Council of Canada Industrial Research Assistance Program (NRC
IRAP)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334980
OncoSec Medical Incorporated / Providence Cancer Institute
(CORVax12), IL-12 expression platform + “S” glycoprotein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04627675
The University of Hong Kong/ Immuno Cure 3 Limited
SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin November 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05102643
Statens Serum Institute, Denmark
DNA; (CoVAXIX) plasmid vaccine
Product Description

Funder
Funder
n/a
Folketing's Finance Committee
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I is expected to start in late 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

National Institute of Chemistry, Slovenia
Plasmid DNA, nanostructured RBD
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Globe Biotech Limited, Bangladesh
DNA plasmid vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Cambridge/ DIOSynVax/ PharmaJet
DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery
systems
Product Description

Funder
Funder
n/a
Innovate UK
Related use
Related use
n/a
Influenza, Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin late fall 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Mediphage Bioceuticals/ University of Waterloo/ Lambton College
DNA; msDNA-VLP
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Immunomic Therapeutics/ EpiVax/ PharmaJet
DNA; plasmid vaccine, needle-free delivery
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Chula Vaccine Research Center
DNA with electroporation
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/
Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/
Region Stockholm
DNA with electroporation
Product Description

Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

National Research Centre, Egypt
DNA; plasmid vaccine S, S1, S2, RBD & N
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Ege University Drug Development and Pharmacokinetic Research Application Center
(ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK)
DNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU
RNA-based
Similar to DNA vaccines, these experimental vaccines provide immunity through
introduction of genetic material (RNA). RNA vaccines can also be potentially
developed more quickly and easily than other vaccines. The BioNTech/Pfizer
vaccine is the first RNA vaccine authorized for human use.
Moderna/ National Institute of Allergy and Infectious Diseases (NIAID)/
Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/
Rovi/ Medidata/ BIOQUAL/ Baxter BioPharma Solutions/ Sanofi/ Recipharm
RNA; LNP-encapsulated mRNA (mRNA 1273), (TAK-919), (TAK-919), (SPIKEVAX™)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and
Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III KidCOVE study positive interim data announced 10/25/2021; Health
Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran
mRNA vaccine) in individuals 12 years of age and older as of 9/16/21; India
granted "Emergency Use Authorization" on 6/29/2021; Clinical update on
mRNA-1273's neutralizing activity against emerging variants announced 6/29/2021;
Submitted authorization application to Swissmedic for use in adolescents on
6/14/2021; Filed for authorization with U.S. FDA for use in adolescents (12-18
years of age) on 6/10/2021; Filed for authorization with Health Canada for use
in adolescents on 6/7/2021; Filed for conditional marketing approval (CMA) with
the European Medicines Agency (EMA) for use in adolescents on 6/7/2021;
Initiated rolling submission process with the U.S. FDA for a Biologics License
Application (BLA) on 6/1/2021; Phase II/III study in adolescents met its primary
immunogenicity endpoint as of 5/25/2021, data is expected to be submitted to
regulators globally in early June 2021; Phase II initial booster data against
variants announced 5/5/2021; World Health Organization (WHO) granted Emergency
Use Listing (EUL) on 4/30/2021; Antibody persistence data published 4/6/2021;
Phase II/III study (KidCOVE) dosed in pediatric population less than 12 years of
age on 3/16/2021; Phase I study of next generation COVID-19 vaccine candidate,
mRNA-1283, dosed on 3/15/2021; First participants dosed with modified COVID-19
vaccines, designed to address the potential need for booster vaccine candidates,
in an amendment to the ongoing Phase II clinical study on 3/10/21; Provided
strategy update for addressing SARS-CoV-2 variants of concern, including a
variant-specific booster candidate (mRNA-1273.351) based on the B.1.351 variant
first identified in the Republic of South Africa, on 2/24/2021; Results from an
in vitro study on neutralization of variants of SARS-CoV-2 by mRNA-1273
vaccine-elicited sera announced January 2021; Phase I/II dosed in Japan
(TAK-919) on 01/21/2021; Switzerland "authorized" on 01/12/2021; U.K. MHRA
granted "temporary authorization" on 01/08/2021; European Commission granted a
"conditional marketing authorization" on 01/06/2021; Israel granted
"authorization to import" on 01/04/2021; Phase III interim safety and primary
efficacy results published on 12/30/2020; Health Canada "authorized" on
12/23/2020; U.S. FDA issued "emergency use authorization" on 12/18/2020; Phase
II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020;
Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on
11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020;
European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III
interim analysis results announced 11/16/2020; Swissmedic started rolling review
on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA)
started rolling review on 10/27/2020; EMA confirmed marketing authorization
submission eligibility on 10/14/2020; Health Canada rolling submission initiated
on 10/13/2020; Study protocol for late-stage clinical trials released September
2020; Phase I interim data from older adult cohorts released Aug 2020 and
published Sep 2020; Phase III COVE study began July 2020, completed enrollment
on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim
results published July 2020; FDA fast track designation granted May 2020;
Selected for US Operation Warp Speed in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04283461, NCT04405076, NCT04470427, NCT04649151, NCT04677660, NCT04712110,
NCT04796896, NCT04847050
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
3 LNP-mRNAs; BNT162
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III topline results from a longer-term analysis in individuals 12 through
15 years of age announced 11/22/2021; U.S. FDA expanded the EUA of a booster
dose to include individuals 18 years of age and older as of 11/19/2021; U.S. FDA
Advisory Committee voted on 10/26/2021 to recommend the FDA grant Emergency Use
Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to <12
years of age; Phase III topline results of the efficacy and safety of a 30-µg
booster dose announced on 10/21/2021; Initial results from Phase II/III study
(in participants 5 to 11 years of age) submitted to the U.S. FDA for the
Agency’s initial review on 9/28/2021; U.S. FDA granted EUA for a booster dose in
individuals 65 years of age and older, and individuals ages 18 through 64 within
certain high-risk groups as of 9/22/2021; Phase II/III study (in participants 5
to 11 years of age) topline results announced 9/20/2021; U.S. FDA approved the
Biologics License Application (BLA) for COMIRNATY® to prevent COVID-19 in
individuals 16 years of age and older on 8/23/2021; U.S. FDA granted Priority
Review designation for the Biologics License Application (BLA) on 7/16/2021 and
the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA
is in January 2022; Vietnam granted "emergency use" approval on 6/12/2021;
European Union expanded Conditional Marketing Authorization (CMA) to include
individuals 12-15 years of age on 5/28/2021; U.S. FDA expanded Emergency Use
Authorization (EUA) to include individuals 12-15 years of age on 5/10/2021;
Announced initiation of Biologics License Application (BLA) with the U.S. FDA on
5/7/2021; Phase III updated topline results announced 4/1/2021; Phase III trial
in adolescents (12-15 years) topline results announced 3/31/2021; Phase I/II/III
continuous study in children 11 years to 6 month old dosed March 2021;
Real-world data gathered by the Israel Ministry of Health announced on
3/11/2021; Evaluation of the safety and immunogenicity of a third dose (30 µg
booster of the current vaccine) 6 to 12 months after receiving initial two-dose
regimen began 2/25/2021; New stability data at standard freezer temperature was
submitted to the U.S. FDA as of 2/19/2021; Phase II/III study in healthy
pregnant women 18 years of age and older dosed 2/18/2021; Results from in vitro
studies on neutralization of variants of SARS-CoV-2 by BNT162b2 vaccine-elicited
sera announced January 2021; Phase I (China) preliminary safety and
immunogenicity data released January 2021; World Health Organization (WHO)
granted Emergency Use Listing (EUL) on 12/31/2021; Argentina authorized under
"emergency registration" on 12/22/2020; European Commission granted a
"conditional marketing authorisation" (CMA) on 12/21/2020, following European
Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued "emergency
use authorization" on 12/11/2020; Mexico COFEPRIS granted "emergency use
authorization" on 12/11/2020; Saudi Food and Drug Authority (SFDA) "approved the
registration" of the vaccine on 12/10/2020; Health Canada "authorized" on
12/9/2020; Bahrain granted "emergency use authorization" on 12/4/2020; U.K. MHRA
granted "temporary authorization for emergency use" on 12/2/2020; Submitted
Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase
III complete analysis results announced 11/18/2020, interim analysis results
announced 11/09/2020; Phase I data published October 2020; FDA approved
late-stage trial enrollment of children 12 years and older in October 2020; EMA
rolling submission initiated on 10/6/2020; Study protocol for late-stage
clinical trials released Sept 2020; Amended protocol to FDA to expand trial
enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA
granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected
for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary
data released Jul 2020, additional data published Aug, Sept, and Dec 2020;
Pre-clinical data released Sept 2020 and Dec 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034825, EudraCT 2020-001038-36, EudraCT 2020-003267-26, NCT04368728,
NCT04380701, NCT04523571, NCT04537949, NCT04588480, NCT04649021, NCT04713553,
NCT04754594
CureVac/Bayer/Novartis
RNA; mRNA (CVnCoV)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI); European Commission; Gates
Foundation; Defense Advanced Research Projects Agency (DARPA); German
Government; European Investment Bank (EIB); German Federal Ministry of Education
and Research (BMBF)
Related use
Related use
n/a
Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV,
DengV, NIPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIb/III final analysis results released 6/30/2021; Phase IIb/III second
interim analysis results released 6/16/2021; Initiated rolling submission with
Swissmedic on 4/19/2021; Initiated rolling submission with European Medicines
Agency (EMA) on 2/12/2021; Phase III trial began December 2020; Phase IIb/III
(HERALD) trial began recruiting December 2020; Phase IIa trial began end of
September 2020; Phase I trial began June 2020, interim results reported November
2020; Pre-clinical data released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-004066-19, NCT04449276, NCT04515147, NCT04652102, NCT04674189,
PER-054-20
ModernaTX, Inc.
RNA; LNP-encapsulated mRNA (mRNA 1273.211)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III began May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04927065
Arcturus/Duke-NUS/ Catalent
RNA; mRNA; (LUNAR-COV19), (ARCT-021)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Emergency Use Authorization filing in Vietnam could be as soon as December 2021;
Phase IIIb (20,000 participants) dosing planned for first week of October 2021;
Phase IIIa (600 participants) on track to initiate by end of September 2021;
Phase IIa of Phase I/II trial began recruiting January 2021; Received approval
to proceed with Phase II study in Singapore (December 2020) and the US (January
2021); Phase I/II interim data released December 2020; Pre-clinical results
released September and December 2020; Phase I/II began August 2020, initial
results expected Q4 2020; Received approval to launch clinical trials in
Singapore end of July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04480957, NCT04668339, NCT04728347, NCT05037097
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech
mRNA (ARCoV)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III expected to begin late May 2021; Phase II began January 2021; Phase Ib
began end of October 2020; Pre-clinical results published September 2020; Phase
I trial began end of June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034112, ChiCTR2000039212, ChiCTR2100041855, NCT04847102
Gennova/ HDT Biotech Corporation
Self-amplifying mRNA vaccine; (HGCO19)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Mid-stage trials expected to begin September 2021; Phase I/II began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2021/04/032688
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science
RNA; mRNA (DS-5670)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II segment of I/II clinical trial began November 2021; Phase I segment of
I/II clinical trial began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Chulalongkorn University/ Chula Vaccine Research Center/University of
Pennsylvania
LNP-mRNA; (ChulaCov19)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began August 2021; Phase I began June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04566276
Elixirgen Therapeutics/ Fujita Health University
srRNA (EXG-5003)
Product Description

Funder
Funder
n/a
Japan Agency for Medical Research and Development (AMED)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Entered into an exclusive licensing agreement with a global pharmaceutical
company (currently undisclosed) in October 2021; Phase I/II began at Fujita
Health University Hospital in May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04863131
Sanofi Pasteur/ Translate Bio
LNP-mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, interim results expected in 3Q 2021; Pre-clinical
results released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Imperial College London/ VacEquity Global Health
RNA; LNP-nCoVsaRNA
Product Description

Funder
Funder
n/a
UK Government
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results published July 2020; Phase I/II trial began June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISRCTN17072692
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)
RNA; LNP-encapsulated mRNA (mRNA 1273.351)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Initial booster data announced May 2021; Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04785144, NCT04405076
Providence Therapeutics Holdings Inc.
PTX-COVID19-B vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin June 2021; Pre-clinical results released May 2021;
Phase I interim data announced May 2021; Phase I dosed January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04765436
ModernaTX, Inc.
RNA; LNP-encapsulated mRNA (mRNA 1283)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed
March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04813796
ModernaTX, Inc.
RNA; LNP-encapsulated (mRNA-1273.529)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Rapidly advancing an Omicron-specific booster candidate (mRNA-1273.529) as of
11/26/2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

GlaxoSmithKline/CureVac
Next-generation multi-valent mRNA-based vaccine; (CV2CoV)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data published 11/18/2021; Pre-clinical data released 5/13/2021;
CureVac and GSK aim to develop a multi-valent candidate vaccine to address
emerging variants for pandemic and endemic use; Development to begin immediately
(February 2021) targeting vaccine availability in 2022, subject to regulatory
approval
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

BiOCAD
RNA; liposome-encapsulated mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal studies began April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Monash Institute of Pharmaceutical Sciences (MIPS)/ Peter Doherty Institute for
Infection and Immunity (Doherty Institute)
mRNA second generation COVID-19 vaccine
Product Description

Funder
Funder
n/a
mRNA Victoria, the agency of the Australian State of Victoria Government
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin October 2021; Preliminary trial results are expected
in the first half of 2022
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

SENAI CIMATEC/ HDT Bio Corp
Lipid-Inorganic Nanoparticle (LION™) formulated replicating RNA-based vaccine,
(HDT-301)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin July 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04844268
Globe Biotech Limited, Bangladesh
D614G variant LNP-encapsulated mRNA; (BANCOVID), (BANGAVAX)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study published June 2021; Phase I/II protocol submitted to
Bangladesh Medical Research Council (BMRC) on 1/17/2021 for approval to begin
clinical trials; Pre-clinical data released September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

CureVac/UK Government (Vaccines Taskforce)
Multiple mRNA vaccine candidates against SARS-CoV-2 variants
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Collaboration to develop and manufacture variant vaccines for commercial supply
and distribution in the UK and its territories was entered in February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

GeneOne Life Science / Houston Methodist
mRNA; (GLS-3000)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Infectious Disease Research Institute/ Amyris, Inc.
saRNA formulated in a NLC
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin mid-2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Max-Planck Institute of Colloids and Interfaces
LNP-encapsulated mRNA encoding S
Product Description

Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Chimeron Bio/ George Mason University's National Center for Biodefense and
Infectious Disease
Self amplifying RNA, self-assembling delivery system
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Centro Nacional Biotecnologia (CNB-CSIC), Spain
RNA; Replicating defective SARS-CoV-2 derived RNAs
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

RNAimmune, Inc.
RNA; several mRNA candidates
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Greenlight Biosciences
mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding RBD
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Ziphius Therapeutics/ Ghent University
RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding
multiple SARS-CoV-2 antigens
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

CanSino Biologics/Precision Nanosystems
RNA; mRNA lipid nanoparticle (mRNA-LNP)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

China CDC / Tongji University / Stermina
RNA; mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

IDIBAPS- Hospital Clinic, Spain
mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Federal Budgetary Research Institution (FBRI) State Research Center of Virology
and Biotechnology "VECTOR"
RNA; mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding VLP
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation
of Vaccination of the University of Antwerp
RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA)
vaccine for high-risk populations
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Selcuk University
mRNA
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU

Replicating viral vector
This involves putting a gene for a viral protein into a different virus (one
that will not cause illness but can replicate). Replication of the viral vector
also produces copies of the viral protein, which triggers an immune response to
that protein. Examples include ebola and dengue vaccines.
Aivita Biomedical, Inc./ National Institute of Health Research and Development,
Ministry of Health Republic of Indonesia
Dendritic cell vaccine AV-COVID-19
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began February 2021; Phase I began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04690387, NCT04685603, NCT04386252, NCT05007496
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Icahn
School of Medicine at Mount Sinai
NDV-HXP-S vaccine, with or without the adjuvant CpG 1018
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04764422
Israel Institute for Biological Research/ Weizmann Institute of Science
rVSV-SARS-CoV-2-S vaccine; (BriLife)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIb/III expected to begin September 2021; Phase III expected to begin
October 2021; Phase I began November 2020 and Phase II began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04608305, NCT04990466
Cellid Co., Ltd./IAVI
AdCLD-CoV19
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study of a revised version of the virus vector vaccine began September
2021; Phase IIa is expected to be dosed in early April 2021; Phase I/IIa trial
began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04666012, NCT05047692
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy
Replicating viral vector, intranasal flu-based RBD (DelNS1-2019-nCoV-RBD-OPT1)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in Hong Kong in April 2021; Phase I/II began in China
during Fall 2020; Approved for clinical trials in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000037782, ChiCTR2000039715, NCT04809389
Institut Pasteur/ Themis/ University of Pittsburgh CVR/ Merck Sharp & Dohme
Replicating viral vector; measles vector (V591); formerly (TMV-083)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika,
MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began September 2020; Animal testing began April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04497298, NCT04498247
Shenzhen Geno-Immune Medical Institute
Covid-19/aAPC vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I reportedly began February 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04299724
Tonix Pharma / Southern Research
Replicating viral vector; horsepox vector expressing S protein; (TNX-1800)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for smallpox, monkeypox
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin during second half of 2021; Preliminary pre-clinical
results reported on 3/17/2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Farmacológicos Veterinarios SAC (FARVET SAC)
Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing S1 protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Farmacológicos Veterinarios SAC (FARVET SAC)
Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

BiOCAD/ IEM
Replicating viral vector, live viral vectored vaccine based on attenuated
influenza virus backbone (intranasal)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Manitoba
Replicating VSV vector-based DC-targeting
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

IAVI/ Merck
Replicating viral vector, replication-competent VSV chimeric virus technology
(VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein; (V590)
Product Description

Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA); Defense Threat
Reduction Agency (DTRA) of the U.S. Department of Defense (DoD)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, Lassa (including
FDA-licensed Ebola vaccine, ERVEBO®)
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in late October 2020; Selected for US Operation Warp
Speed in April 2020; clinical studies to start in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04569786
Federal Budgetary Research Institution (FBRI) State Research Center of Virology
and Biotechnology "VECTOR"
Replicating viral vector; measles vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Fundacao Oswaldo Cruz and Instituto Buntantan
Attenuated Influenza expressing an antigenic portion of the Spike protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Federal Budgetary Research Institution (FBRI) State Research Center of Virology
and Biotechnology "VECTOR"
Replicating viral vector; VSV vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

The Lancaster University, UK
Avian paramyxovirus vector (APMV)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

DZIF - German Center for Infection Research/ CanVirex AG
Measles virus (S, N targets)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Zika, H7N9, CHIKV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Western Ontario
Replicating viral vector; VSV-S
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Aurobindo
VSV-S
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Zydus Cadila Healthcare Limited
Replicating viral vector; measles vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Wisconsin-Madison / FluGen/ Bharat Biotech
M2-deficient single replication (M2SR) influenza vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I trial in fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

KU Leuven
Replicating viral vector; YF17D Vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Federal Budgetary Research Institution (FBRI) State Research Center of Virology
and Biotechnology "VECTOR"
Replicating viral vector, recombinant vaccine based on Influenza A virus, for
the prevention of COVID-19 (intranasal)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU

Non-replicating viral vector
This approach is similar to replicating viral vector vaccines in that a viral
gene is added to a different, non-replicating, virus and delivered to the
vaccine recipient.
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation
Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA,
the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
Non replicating viral vector; COVID-19 Vaccine AstraZeneca in the U.K. (formerly
AZD1222 and ChAdOx1), Covishield in India, (Vaxzevria)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/
Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the
Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB,
plague
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III safety and efficacy data published September 2021; Tolerability and
immunogenicity results after a late second dose or a third dose released on
6/28/2021; Real-world data on vaccine effectiveness against hospitalizations due
to the Delta variant released 6/14/2021; Japan granted authorization for
"emergency use" on 5/21/2021; EMA updated guidance on very rare side effects
announced 4/7/2021; Phase II dosing paused in children between the ages of 6 and
17 years pending MHRA review as of 4/6/2021; Phase III primary analysis (U.S.
trial) results announced 3/25/2021; Phase III interim analysis (U.S. trial)
results announced 3/22/2021; World Health Organization (WHO) granted Emergency
Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6
and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and
Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European
Union (EU) granted "conditional marketing authorisation" on 1/29/2021; Brazil
granted "temporary authorization for emergency use" on 1/17/2021; Pakistan
granted "emergency use authorization" on 1/15/2021; India granted "emergency use
authorisation" as well as Dominican Republic, El Salvador, Mexico and Morocco as
of 1/6/2021; Argentina authorized under "emergency registration" on 12/30/2020;
U.K. "authorised for emergency supply" on 12/30/2020; Phase I/II data (w/
booster dose) published on 12/17/2020; Phase III trials interim analysis results
published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled
interim analysis results released on 11/23/2020; Phase II/III trial interim
results released Nov 2020; Study protocol for late-stage clinical trials
released September 2020; AstraZeneca clinical trials resumed globally (in the UK
on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the
US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow
independent review of safety data on 9/8/2020; Phase III trial began Jun 2020
and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial
interim results released Jul 2020; Selected for US Operation Warp Speed in May
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32,
ISRCTN15638344, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674,
NCT04516746, NCT04540393, NCT04568031, NCT04686773, PACTR202005681895696,
PACTR202006922165132
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent
BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/
Sanofi/ Merck
Ad26.COV2-S (or JNJ-78436725), Non replicating viral vector; Ad26 (alone or with
MVA boost)
Product Description

Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, HIV, RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Health Canada fully "approved" the vaccine in individuals 18 years of age and
older on 11/24/2021; Phase I/IIa sub-study results published 7/14/2021; Johnson
& Johnson statement on COVID-19 vaccine released 7/12/2021; Data on neutralizing
activity against emerging variants announced 7/1/2021; U.K. MHRA granted
"conditional marketing authorization" on 5/28/2021; CDC and FDA lift recommended
pause on vaccine use in U.S. on 4/23/2021; Phase III ENSEMBLE primary data
published on 4/21/2021; CDC and FDA recommended a pause on vaccine use in the
U.S. as of 4/13/2021; Phase IIa trial expanded to include adolescents 12-17
years of age as of 4/2/2021; WHO issued "emergency use listing" on 3/12/2021;
Granted Conditional Marketing Authorization by European Commission on 3/11/2021;
Granted "Interim Order (IO) authorization" for emergency use by Health Canada on
3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has
recommended the first single-shot COVID-19 vaccine for individuals 18 years of
age and older on 2/28/2021; U.S. FDA issued "emergency use authorization" on
2/27/2021; Submitted "emergency use listing" to the World Health Organization
(WHO) on 2/19/2021; Submitted "conditional marketing authorisation application"
to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted
application for "emergency use authorization" to the U.S. FDA on 2/4/2021; Phase
III interim analysis results announced 1/29/2021; Phase I/IIa interim results
published 1/13/2021; Phase III trial to study the safety and efficacy of a
two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE)
resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as
of 12/17/2020, interim data expected by the end of January 2021; Janssen
Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow
independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE)
began and study protocol released September 2020; Phase I/IIa began end of July
2020, interim results released September 2020; Animal study results published
July and September 2020; Selected for US Operation Warp Speed in February 2020
and awarded funding in August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002584-63, ISRCTN14722499, NCT04436276, NCT04505722, NCT04509947,
NCT04535453, NCT04614948, NCT04765384
Gamaleya Research Institute
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
Product Description

Funder
Funder
n/a
Russian Direct Investment Fund (RDIF)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Final results of trials are expected to be ready by October 2021; Demonstrated
efficacy based on the analysis of data from vaccinated persons announced on
4/19/2021; Started rolling review process with the European Medicines Agency
(EMA) on 3/4/2021; Authorized for "emergency use" in 39 countries as of March
2021; Phase III interim analysis results published on 2/2/2021; "Registered" in
Belarus in December 2020; Phase III final control point data analysis results
released December 2020, interim data analysis results released November 2020;
Phase III (post-registration) trial began September 2020; Phase I/2 began June
2020, results published September 2020; Russian Ministry of Health "registered"
vaccine in August 2020, Mass production expected to begin September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04436471, NCT04437875, NCT04530396, NCT04564716, NCT04587219, NCT04640233,
NCT04642339, NCT04656613, NCT04713488, NCT04741061
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV), (Convidecia™)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Authorized for "emergency use" in Argentina, Chile, Hungary, Pakistan, and
Mexico, and for "conditional approval" in China as of June 2021; Filed
"conditional marketing authorization" with China's National Medical Products
Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II
began April 2020, initial results released May 2020, mid-phase results released
July 2020; China’s Central Military Commission "approved the use of the vaccine
by the military" in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147,
NCT04526990, NCT04540419, NCT04552366, NCT04566770, NCT04568811
AstraZeneca
Non-replicating viral vector; (AZD2816)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III dosed end of June 2021, in both previously vaccinated (with two
doses of Vaxzevria or an mRNA vaccine) and unvaccinated adults to determine the
safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19
caused by variant strains of the SARS-CoV-2 virus
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04973449
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases
Lazzaro Spallanzani
Non-replicating viral vector; replication defective simian adenovirus encoding
SARS-CoV-2 S (GRAd-CoV2)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II preliminary data announced July 2021; Phase II/III (COVITAR) study
began March 2021; Phase I advanced to second set of three cohorts (aged 65-85
years) in November 2020; Phase I began August 2020, completed the first set of
three cohorts (aged 18-55 years), preliminary results announced November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002835-31, EudraCT 2020-005915-39, NCT04528641, NCT04791423
Vaxart/ Emergent BioSolutions
Non-replicating viral vector; Oral Vaccine platform
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV,
VEE
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II dosed October 2021; Phase I preliminary data announced 2/3/2021; Phase
I dosed October 2020; FDA clearance for Phase I trial received September 2020,
recruiment expected to begin September 2020; Pre-clinical results released
September 2020; Data from ongoing animal challenge study released October and
November 2020. Phase 2 trials in India begin Feb 2022.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04563702, NCT05067933
BIOCAD
Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5)-RBD (Receptor
Binding Domain)-S Vaccine, (BCD-250)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05037188
ImmunityBio/ NantKwest
Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid;
(subcutaneous, oral, and sublingual delivery)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV,
cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II/III trial expected to begin Q3 2021 and will study the efficacy,
safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost
in participants who have already received a spike-only antibody-based vaccine;
Expanded trials to test vaccine candidate as a ‘universal boost’ in vaccinated
subjects and received approval to test intranasal spray in South Africa as of
May 2021; Phase I/II supplemental vaccine boost trial began April 2021; Phase Ib
preliminary findings reported on 4/8/2021; Phase I interim safety data announced
on 3/15/2021; Phase I dosed in South Africa and the U.S. in March 2021; FDA
authorized the expansion of the active Phase I trial and a second trial to test
a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a
room-temperature oral or sublingual boost; Phase I interim data announced
November 2020; Pre-clinical data released December, November, and July 2020;
Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp
Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04591717, NCT04710303, NCT04732468, NCT04843722, NCT04845191
Shenzhen Geno-Immune Medical Institute
LV-SMENP-DC vaccine and antigen-specific CTLs
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II reportedly began March 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04276896
Bharat Biotech International Limited
BBV154; adenovirus vectored, intranasal vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04751682
CyanVac LLC
Intranasal PIV5-vectored vaccine expressing SARS-CoV-2 spike protein;
(CVXGA1-001)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04973449
City of Hope Medical Center
MVA-based SARS-CoV-2 vaccine; (COH04S1)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin August 2021; Phase I dosed December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04639466, NCT04977024
Gritstone Oncology, Inc.
Chimpanzee Adenovirus serotype 68 (chAd) and Self-Amplifying mRNA (SAM) vectors
expressing either spike alone, or spike plus additional SARS-CoV-2 T cell
epitopes (TCE)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04776317
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/
Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical
Center/ Ludwig-Maximilians University of Munich
Non-replicating viral vector; MVA-S encoded
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for many pathogens
Anticipated Next Steps
Anticipated Next Steps
n/a
Spike protein of the vector vaccine has now been modified and clinical testing
will resume as of 7/16/2021; Phase I/II expected to begin July 2021; Clinical
testing suspended January 2021, Phase II postponed until further notice; Phase I
dosed October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04569383, NCT04895449
Altimmune / University of Alabama at Birmingham/ Summit Biosciences
AdCOVID; single-dose, intranasal vaccine; non replicating viral vector;
adenovirus-based NasoVAX expressing spike protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I data expected to be released June 2021; Additional pre-clinical data
released March and May 2021; Phase I commenced enrollment on 2/25/2021; FDA
issued clinical hold for planned Phase I trial on 12/22/2020; Pre-clinical data
released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04679909
McMaster University/ Canadian Institutes of Health Research (CIHR)
Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines
expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin November 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05094609
Tetherex Pharmaceuticals Corporation
Adneviral vector vaccine, (SC-Ad6-1)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04839042
Institut Pasteur/ TheraVectys
Intranasal lentiviral vector vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results published December 2020; Animal study results released July
2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Valo Therapeutics Ltd/ ImmunoScape
Adenovirus-based + HLA-matched peptides (Pan-Corona)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

iosBIO (formerly Stabilitech Biopharma Ltd)
Oral Ad5 S; (OraPro-Covid-19)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Helsinki/ University of Eastern Finland/ Rokote Laboratories
Finland Ltd
Ad 5 vector for intranasal administration
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Bharat Biotech/ Thomas Jefferson University
Recombinant deactivated rabies virus containing S1; (CoraVax)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data published October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Massachusetts Eye and Ear/ AveXis, a Novartis Company/ Viralgen/ Aldevron/
Catalent/ Penn Medicine
AAVCOVID, Adeno-associated viral vector (AAV), spike protein
Product Description

Funder
Funder
n/a
Gates Foundation
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released January 2021; Phase I to begin second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch
Non-replicating viral vector; MVA encoded VLP
Product Description

Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)/National
Institutes of Health (NIH)
Related use
Related use
n/a
Same platform as vaccine candidates for LASV, EBOV, MARV, HIV
Anticipated Next Steps
Anticipated Next Steps
n/a
Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to
support the ongoing design, construction, and preclinical testing in preparation
for human clinical trials
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical
Sciences, PLA of China
Ad5-nCoV
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I recruitment began end of September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04552366
Globe Biotech Limited, Bangladesh
Adenovirus Type 5 Vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO,
Thailand
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Ankara University
Adenovirus-based
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

IDIBAPS- Hospital Clinic, Spain
MVA-S
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Greffex
Non-replicating viral vector; Ad5 S (GREVAX™ platform)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Centro Nacional Biotecnologia (CNB-CSIC), Spain
Non-replicating viral vector, MVA expressing structural proteins
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria,
Leishmania
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

ID Pharma
Sendai virus vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

National Research Centre, Egypt
Influenza A H1N1 vector
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Georgia/ University of Iowa
Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine
expressing the spike protein
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Erciyes University
Adeno5-based
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU
Virus-like particle
Virus-like particle (VLP) vaccines closely resemble viruses but are
non-infectious because they contain no viral genetic material. Since VLPs cannot
replicate, they provide a safer alternative to attenuated viruses. Examples
include the HPV vaccine.
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing
Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate,
targeting COVID-19, SARS, and MERS, spike protein (VBI-2900)
Product Description

Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II trial of VBI-2902a expected to begin March 2021; Phase I trial of
VBI-2905, targeting the B.1.351 variant, expected to begin mid-year 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04773665
Arizona State University
Plasmid driven production of virus like particles (VLPs) containing S, M, N and
E proteins of SARS-CoV-2
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Arizona State University
Myxoma virus co-expressing S, M, N and E proteins
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Max-Planck Institute for Dynamics of Complex Technical Systems
VLP
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Tampere University
VLPs produced in BEVS
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Manitoba
Virus-like particle-based dendritic cell-targeting vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

ARTES Biotechnology
VLP; eVLP
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for malaria
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

University of Sao Paulo
VLPs peptides/whole virus
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Imophoron Ltd / Bristol University's Max Planck Centre
VLP; ADDomerTM multiepitope display
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Doherty Institute
VLP; unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj
Hospital
VLP + Adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Medicago Inc./ Dynavax
VLP (CoVLP)+ Adjuvant (CpG 1018)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start mid-July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols
S protein integrated in HIV VLPs
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Saiba GmbH
VLP; virus-like particle, based on RBD displayed on virus-like particle
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Medicago Inc./ GSK
VLP (CoVLP)+ Adjuvant
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

OSIVAX
VLP (COVID-19 and SARS1)
Product Description

Funder
Funder
n/a
European Innovation Council (EIC)
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Bezmialem Vakif University
VLP
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Navarrabiomed, Oncoimmunology group
Virus-like particles, lentivirus, and baculovirus vehicles
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Radboud University
ABNCoV2 capsid virus-like particle, formulated with and without the adjuvant
MF59
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I of I/II study began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04839146, NCT05329220
Scientific and Technological Research Council of Turkey (TÜBITAK)/ Middle East
Technical University/ Bilkent University
VLP
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin early June 2021; Phase I dosed end of March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04818281
Icosavax
VLP displaying the SARS-CoV-2 receptor-binding domain (RBD); (IVX-411)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began June 2021; Pre-clinical results published October 2020, Topline
results published March 2022.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Serum Institute of India/ Accelagen Pty/ SpyBiotech
RBD SARS-CoV-2 HBsAg VLP vaccine
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I of follow up Phase I/II clinical trial adjuvanted with CpG 1018 dosed
December 2020; Phase I/II began September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12620000817943, ACTRN12620001308987
Medicago Inc./ GlaxoSmithKline
VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjuvants; (CoVLP)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile
virus, and cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II interim results released May 2021; Health Canada initiated review of
the Interim Order (IO) rolling submission on 4/19/2021; Phase III portion of the
ongoing Phase II/III trial began March 2021;Phase II portion of the Phase II/III
trial dosed December 2020; Phase II/III began recruiting November 2020; Phase I
interim results released November 2020; Phase I began July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04450004, NCT04636697, NCT04662697
Developer / Researcher

Product Description
PRE
I
II
III
RR
AU

Other Vaccines
From a gene-encoded antibody vaccine to a self-assembling vaccine and more,
these are the vaccines being developed that do not fall easily into one of the
other product categories or details about its category are not publicly
available.
United Biomedical (UBI)/ c19
Unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Clinical testing expected to begin early September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Oragenics (Noachis Terra)/ Aragen Bioscience
TerraCoV2
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to start in early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

NidoVax
unknown; IMT504 technology
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Vault Pharma/ University of California Los Angeles
nanoparticles (vaults) as second-line defense of infection
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Tulane University
Unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Catholic University/ Millennium Institute of Immunology and Immunotherapy/
Technological Consortium in Clinical Molecular Biomedicine, Chile
Unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the
Massachusetts General Hospital
Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with
biotinylated immunogenic peptides)
Product Description

Funder
Funder
n/a
Analog Devices Foundation
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results by October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Vivaldi Biosciences/ Esco Aster Pte Ltd
Chimeric vaccine (coronavirus and influenza)
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Adeleke University
Unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

AbVision
AVI-205
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Codiak BioSciences/ Ragon Institute
exoVACC exome platform
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Precision Vaccines Program at Boston Children's Hospital
Unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Vir Biotechnology / GSK
Unknown
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

ISR Immune System Regulation
ISR-50
Product Description

Funder
Funder
n/a
Unknown
Related use
Related use
n/a

Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results expected in Q2 2020, Phase I begins Q4 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a

Developer / Researcher

Product Description
PRE
I
II
III
RR
AU

The race to produce a COVID-19 vaccine is multifaceted—involving new research on
many levels, enormous amounts of fundraising, and unprecedented international
cooperation. Check back often with our COVID-19 Vaccine Tracker.

See both the vaccine and treatment approaches being developed at our combined
COVID-19 Treatment and Vaccine Tracker.

‍

Back to top

© 2020 Milken Institute and First Person

covid19@milkeninstitute.org‍


@MilkenInstitute


Credit



Data sourced from FasterCures, a center of 
the Milken Institute.

Interactive visualization by FirstPerson, a design & storytelling company.

Connect



Covid-19 vaccine tracker

Mobile and tablet experiences coming soon
View treatment and vaccine tracker data here.